AMD announced its first life sciences collaboration with AI-based drug developer Absci, providing its hardware and software for Absci’s AI drug discovery. Despite AMD also investing $20m in Absci, its shares fell 4% after HSBC analyst Frank Lee downgraded the firm from “Buy” to “Reduce” and cut its price target by 18%, suggesting AMD will continue trailing market leader Nvidia. This is AMD’s first life-sciences partnership.
Nevada unveils new statewide data classification policy months after cyberattack
Eric Neugeboren reports: Nevada’s IT agency has rolled out a new policy aimed at standardizing the privacy of state data, months after a massive cyberattack crippled certain
